Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 11, 2016 8:02 AM EDTHACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 11, 2016 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (Nasdaq:Â BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2016.
"We achieved a major milestone for Brainstorm, with the announcement, in July, of positive data from our Phase 2 trial of NurOwn® in Amyotrophic Lateral Sclerosis, or ALS," said Chaim Lebovits, Chief Executive Officer of BrainStorm. "This study, which was... More
